Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

PATH-FOR-YOUNG Personalized Adjuvant Treatment for HR+/HER2- breast cancer FOR YOUNG patients

Coordinator
Unicancer, France
Runs
1 January 2025 to 31 December 2031
Status
Running
EU funding
€9.5m
Total cost
—
Partners
27 organisations in 15 countries
Type
Research and Innovation Action
Grant agreement
101156800

What the project is doing

In the project's own words, from its summary on CORDIS.

Worldwide, ~7 million women live with or beyond Breast Cancer (BC), as 10-year survival rates exceeding 80% for early-stage (I-III) BC. Premenopausal BC accounts for 25% in the EU and 55% in low/middle income countries. Most premenopausal women with BC have high risk of recurrence, therefore standard treatment includes adjuvant chemo- (CT) and endocrine therapy (ET). However, treatment has substantial physical, emotional and social burden, which is often more pressing for younger compared to older patients.

Gene-expression assays are used for post-menopausal patients to identify women who can safely forego CT without detriment on clinical outcomes, preserving Quality of Life (QOL). However, a definitive study has yet to be conducted among premenopausal women with high-risk HR+HER2-BC. The primary objective of PATH-FOR-YOUNG is to conduct a pragmatic randomized controlled trial (RCT) with 5000 patients validating the use of a gene-expression assay to drive adjuvant treatment decisions in this target population.

PATH-FOR-YOUNG aims to achieve its objective in 7 years. The project (i) builds on and complements an ongoing twin RCT to ensure timely recruitment, (ii) leverages on a large international consortium of oncologists, pathologists, patient representatives, psychologists, sociologists, ethics and communication experts, biostatisticians, health economists, and technology providers, to assure complementary and multidisciplinary expertise, and (iii) highlights patient-engagement, participatory care, and early involvement of end users.

PATH-FOR-YOUNG will also study implementation of digital self-management to support patients throughout the cancer journey and particularly while on ET to improve QOL and medication adherence. A full HTA will ensure a path towards cross-country implementation. PATH-FOR-YOUNG has the ambition to improve BC care, fully integrating the predictive, personalized, preventive, and participatory principles of health management.

Topics

Who is involved

OrganisationCityCountryRole
UnicancerParisFranceCoordinator
Grupo Argentino De Investigacion Clinica En Oncologia Asociacion CivilRosarioARParticipant
ANZ Breast Cancer Trials Group LtdNewcastleAustraliaAssociatedpartner
The University of SydneySydneyAustraliaAssociatedpartner
Association Hospitaliere De Bruxelles-Centre Hospitalier Universitaire Jules BordetAnderlechtBelgiumParticipant
Breast International Group, B.i.g.aisblBruxellesBelgiumParticipant
Instituto D'Or de Pesquisa e EnsinoNiteróiBrazilAssociatedpartner
Latin American Cooperative Oncology GroupPorto AlegreBrazilAssociatedpartner
Elliniki Synergazomeni Ogkologiki OmadaAthensGreeceParticipant
Gr Espanol De Estudio Y Tratamientode Intensific. Y Otras Estrateg.experiment. En Tumores Solidos - Grupo SoltiBarcelonaSpainParticipant
Innovandum Health SLValenciaSpainParticipant
Universidad De Castilla - La ManchaCiudad RealSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Institut Gustave RoussyVillejuifFranceParticipant
KlineoClichyFranceParticipant
ResilienceParisFranceParticipant
Cancer Trials Ireland Company Limited by GuaranteeDublinIrelandParticipant
Clinical Research Technology SRLSalernoItalyParticipant
Europa Donna the European Breast Cancer CoalitionMilanoItalyParticipant
Gruppo Oncologico Italiano Di Ricerca ClinicaParmaItalyParticipant
Universita Degli Studi Di TorinoTorinoItalyParticipant
Stichting Eupati FoundationUtrechtNetherlandsParticipant
Grupo De Estudios Clinicos Oncologico Peruano GecoperuSantiago de SurcoPEParticipant
Central and East European Oncology GroupGdanskPolandParticipant
Europa Donna Slovensko Zdruzenje Za Boj Proti Raku DojkLjubljanaSloveniaThird party
University of WarwickCoventryUnited KingdomParticipant
Dana-Farber Cancer Institute IncBoston MaUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI